Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270923
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
3700±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270923
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-(3-chlorophenyl)propanamido]acetamido}acetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL508126
Type:
Small organic molecule
Emp. Form.:
C73H103ClN20O18S2
Mol. Mass.:
1648.305
SMILES:
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:104.109,72.75,28.36,50.60,4.4,89.91,42.44,83.87,wD:61.71,16.25,46.48,108.112,(32.38,-22.38,;32.38,-23.9,;33.72,-24.68,;31.03,-24.68,;31.03,-26.2,;29.7,-26.98,;28.36,-26.22,;28.36,-24.69,;27.05,-26.98,;25.72,-26.2,;24.4,-26.99,;24.4,-28.54,;23.06,-26.22,;21.71,-26.98,;20.36,-26.23,;20.36,-24.71,;19.04,-26.99,;19.04,-28.55,;20.38,-29.33,;21.71,-28.55,;23.04,-29.33,;23.04,-30.86,;21.71,-31.64,;21.71,-33.17,;20.38,-30.86,;17.72,-26.2,;16.4,-26.99,;16.4,-28.54,;15.06,-26.22,;15.06,-24.7,;16.4,-23.92,;17.81,-24.57,;18.85,-23.43,;18.08,-22.09,;16.57,-22.39,;13.7,-26.94,;12.34,-26.22,;12.34,-24.7,;11.02,-26.98,;9.72,-26.16,;8.41,-26.98,;8.41,-28.53,;7.08,-26.2,;5.74,-26.97,;4.41,-26.19,;4.41,-24.67,;3.09,-26.96,;1.77,-26.17,;.45,-26.97,;.45,-28.52,;-.88,-26.2,;-.88,-24.67,;.45,-23.9,;1.79,-24.68,;3.13,-23.92,;3.13,-22.38,;1.81,-21.61,;.47,-22.38,;-2.24,-26.91,;-3.6,-26.19,;-3.6,-24.66,;-4.93,-26.96,;-4.93,-28.5,;-3.61,-29.27,;-3.61,-30.82,;-2.24,-31.52,;-2.26,-33.06,;-3.59,-33.8,;-.94,-33.83,;-6.22,-26.11,;-7.51,-26.94,;-7.51,-28.47,;-8.85,-26.17,;-10.16,-26.84,;-8.85,-24.63,;-7.5,-23.85,;-7.5,-22.33,;-8.83,-21.57,;-6.17,-21.56,;3.09,-28.51,;4.63,-28.52,;1.55,-28.52,;3.08,-30.05,;7.08,-24.68,;5.75,-23.92,;8.41,-23.9,;32.38,-26.98,;32.38,-28.53,;33.71,-26.21,;35.05,-26.97,;36.37,-26.2,;36.37,-24.68,;35.06,-23.91,;35.07,-22.38,;36.41,-21.61,;36.41,-20.07,;37.73,-22.38,;37.72,-23.92,;35.05,-28.52,;33.72,-29.29,;36.38,-29.29,;37.8,-28.67,;38.82,-29.82,;38.05,-31.13,;36.55,-30.81,;35.41,-31.84,;33.94,-31.38,;35.72,-33.35,;34.63,-34.44,;33.15,-34.05,;32.06,-35.14,;35.03,-35.93,;33.94,-37.02,;36.51,-36.32,)|
Structure:
Search PDB for entries with ligand similarity: